Department of Pharmacy, Geriatric Hospital of Hainan, Haikou, 571100 Hainan, China.
Department of Respiratory Medicine, Danzhou People's Hospital, Danzhou, 571700 Hainan, China.
Comput Math Methods Med. 2022 Aug 8;2022:1191205. doi: 10.1155/2022/1191205. eCollection 2022.
To explore the associations between glucocorticoid use and the clinical outcome of patients with severe pneumonia.
Medical databases including PubMed, EMBASE, and ScienceDirect were searched for relevant literature. Two independent researchers extracted the primary endpoint from the included literature. The Cochrane test and statistics were used to evaluate the interstudy heterogeneity. The combined risk estimates were calculated by random effect model, and the source of heterogeneity was evaluated by subgroup analysis. Funnel plot and Egger's test were used to assess publication bias. < 0.05 denoted statistical significance.
A total of 12 literature, including 8171 patients with 1083 deaths, were included in this study for meta-analysis. The use of glucocorticoids significantly increased the mortality (RR = 1.44, 95% CI: 1.13, 1.84, < 0.001), the risk of requiring mechanical ventilation (RR = 1.62, 95% CI: 1.30, 2.02, < 0.001), and the incidence of nosocomial infection (RR = 1.36, 95% CI: 1.01, 1.82, = 0.04) in patients with severe pneumonia as compared with the control group. In addition, the use of glucocorticoids did not seem to be associated with length of treatment in the intensive care unit (mean difference = 1.47, 95% CI: -1.04, 3.96, = 0.25) and the length of hospital stay (mean difference = 0.55, 95% CI: -3.90, 4.99, = 0.81).
The use of glucocorticoids may increase the mortality, the incidence of hospital-acquired pneumonia, and the need for mechanical ventilation in patients with severe pneumonia.
探讨糖皮质激素的使用与重症肺炎患者临床结局之间的关联。
检索了 PubMed、EMBASE 和 ScienceDirect 等医学数据库,以查找相关文献。两名独立的研究人员从纳入文献中提取主要终点。采用 Cochrane 检验和 Q 检验评估各研究间的异质性。采用随机效应模型计算合并风险估计值,并通过亚组分析评估异质性来源。采用漏斗图和 Egger 检验评估发表偏倚。 < 0.05 表示具有统计学意义。
本研究共纳入 12 项研究,共计 8171 例患者(1083 例死亡)进行荟萃分析。糖皮质激素的使用显著增加了死亡率(RR = 1.44,95%CI:1.13,1.84, < 0.001)、需要机械通气的风险(RR = 1.62,95%CI:1.30,2.02, < 0.001)和医院获得性感染的发生率(RR = 1.36,95%CI:1.01,1.82, = 0.04),与对照组相比。此外,糖皮质激素的使用似乎与重症肺炎患者在重症监护病房的治疗时间(均数差= 1.47,95%CI:-1.04,3.96, = 0.25)和住院时间(均数差= 0.55,95%CI:-3.90,4.99, = 0.81)无关。
糖皮质激素的使用可能会增加重症肺炎患者的死亡率、医院获得性肺炎的发生率以及机械通气的需求。